A meta-analysis published in The Lancet Diabetes & Endocrinology is suggestive of a class cardioprotective effect for the glucagon-like peptide-1 receptor agonists.
The results of the Exenatide Study of Cardiovascular Event Lowering study show that the glucagon-like peptide-1 receptor agonist has a neutral cardiovascular effect, the investigators have reported at the EASD annual meeting, in Lisbon, Portugal.
Editorial Board member Sanjay Kalra presents a pragmatic approach to the use of glucagon-like peptide-1 receptor agonists in patients affected by acute myocardial infarction.
Editorial board member John Wilding outlines key moments from the 52nd annual meeting of the European Association for the Study of Diabetes in Munich, Germany.
With four GLP-1 receptor agonists now having published cardiovascular outcome data, medwireNews takes a look at how the experts are interpreting the conflicting findings, and what they mean for prescribing decisions.